- Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment options
- The company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 disease
- Delic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in the United States
- With 13 clinics already in operation, Delic is eyeing expansion as it seeks to ensure 60-70% of Americans are within a 45-minute drive to its clinics
The latest data from the World Health Organization (“WHO”) shows that the COVID-19 pandemic has triggered a 25% increase in the number of cases of anxiety and depression globally. Caused by multiple exacerbating factors, including loneliness, suffering and death, fear of infection, financial worries, and grief, this increased prevalence has also coincided with the substantial disruption in mental health services, creating a gaping hole in the care of people leaving with these conditions (https://ibn.fm/Tzpcj).
Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has stepped up its efforts as it looks to fill the gaps exposed by COVID-19’s battering of the health sector. “Our mission is to heal the planet. We want to help heal the…
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
